Turtle Creek Wealth Advisors LLC Cuts Holdings in MiMedx Group, Inc $MDXG

Turtle Creek Wealth Advisors LLC reduced its position in MiMedx Group, Inc (NASDAQ:MDXG) by 8.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 166,700 shares of the company’s stock after selling 15,000 shares during the quarter. Turtle Creek Wealth Advisors LLC owned about 0.11% of MiMedx Group worth $1,019,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. CWM LLC increased its holdings in MiMedx Group by 63.8% in the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after purchasing an additional 1,892 shares in the last quarter. HighMark Wealth Management LLC increased its holdings in MiMedx Group by 23.3% in the 2nd quarter. HighMark Wealth Management LLC now owns 53,000 shares of the company’s stock valued at $324,000 after purchasing an additional 10,000 shares in the last quarter. Truist Financial Corp increased its holdings in MiMedx Group by 80.8% in the 2nd quarter. Truist Financial Corp now owns 96,250 shares of the company’s stock valued at $588,000 after purchasing an additional 43,000 shares in the last quarter. HB Wealth Management LLC acquired a new stake in MiMedx Group in the 2nd quarter valued at $156,000. Finally, Harbor Capital Advisors Inc. increased its holdings in MiMedx Group by 12.0% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 1,169,195 shares of the company’s stock valued at $7,144,000 after purchasing an additional 125,519 shares in the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on MDXG shares. Wall Street Zen upgraded MiMedx Group from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald increased their price target on MiMedx Group from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, July 31st. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, MiMedx Group has an average rating of “Moderate Buy” and a consensus target price of $12.00.

MiMedx Group Stock Up 2.0%

Shares of MiMedx Group stock opened at $6.71 on Thursday. The business has a 50-day moving average of $7.05 and a 200-day moving average of $6.81. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 3.90. The company has a market capitalization of $992.81 million, a PE ratio of 31.95 and a beta of 1.73. MiMedx Group, Inc has a 1-year low of $5.59 and a 1-year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Monday, November 13th. The company reported ($0.03) earnings per share for the quarter. The business had revenue of $67.69 million for the quarter. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. As a group, equities analysts forecast that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.